OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

Nov 14, 2016

NEW YORK (GenomeWeb) – OpGen and Merck announced today that they will collaborate to develop rapid diagnostics and informatics tools for antibiotic resistance.

Under the terms of the deal, Merck will give OpGen access to its library of 200,000 bacterial pathogens in order to support OpGen's development of rapid DNA tests and a genomic database of antibiotic-resistant pathogens.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Startup Novel Microdevices Developing Rapid Point-of-Care MDx System for STIs

Sponsorships